血脂与结直肠癌肝转移关系的临床研究

目的:检测结直肠癌患者的血脂水平,包括总胆固醇(TC)和甘油三酯(TG),探讨血脂异常与结直肠癌肝转移的关系.方法:收集本院282例结直肠癌患者的临床病理资料并检测空腹血脂水平.测定患者血清白蛋白和计算体重指数(BMI)评估患者的营养状态,对血脂等临床病理因素与结直肠癌肝转移的关系进行统计学分析.结果:结直肠癌肝转移患者的高胆固醇血症及高甘油三酯血症比率高于无肝转移者,差异有统计学意义(P＜0.05).多元Logistic回归分析显示,高胆固醇血症是结直肠癌发生肝转移的独立危险因素之一,而与高甘油三酯血症无关.结论:高胆固醇血症与结直肠癌肝转移相关,血脂水平的增高可能促进结直肠癌肝转移.     

多发性骨髓瘤患者血清胆固醇水平的临床意义

 目的　探讨多发性骨髓瘤（MM）患者血清胆固醇水平变化及其与分型、分期的关系。方法　回顾分析65例MM患者诊断时血脂水平,包括总胆固醇（TC）、三酰甘油（TG）、高密度脂蛋白胆固醇（HDL-C）、低密度脂蛋白胆固醇（LDL-C）、载脂蛋白A1（Apo-A1）和载脂蛋白B（Apo-B）,探讨血脂参数与MM患者免疫球蛋白类型和临床分期关系。以健康体检者30例作为对照组。结果　65例MM患者中IgG型35例（53.85 %）,Ⅲ期41例（63.1 %）,MM患者血清TC、HDL-C、 LDL-C、Apo-A1和Apo-B明显低于对照组 （P＜0.05）,两组TG差异无统计学意义（P＞0.05）;除1例IgD型外,其余64例患者中,IgG和IgA型患者血清TC、HDL-C、LDL-C、Apo-A1和Apo-B均显著低于轻链型（P＜0.05）,TG水平在不同Ig类型患者间无差别;Ⅲ期患者血清TC、HDL-C、LDL-C和Apo-A1均显著低于Ⅰ期患者和对照组（P均＜0.05）,且Ⅱ期患者血清LDL-C 也显著低于Ⅰ期患者（P＜0.05）。结论　MM患者存在低胆固醇血症,且血清胆固醇水平与疾病分期有关。     

结直肠癌术后辅助化疗对血脂变化的影响

目的:探讨结直肠癌患者术后辅助化疗前后血脂水平的变化及不同化疗方案对血脂变化的影响。方法:对127例结直肠癌患者术后辅助化疗前后总胆固醇（TC）、甘油三酯(TG)、低密度脂蛋白(LDL)、高密度脂蛋白(HDL)水平进行测定并比较分析。结果:化疗后,TG、HDL、LDL水平较化疗前升高,差异有统计学意义（P＜0.05）。TC值较化疗前增高,但差异无统计学意义（P＞0.05）。含奥沙利铂的化疗方案与卡培他滨单药方案相比对TC、TG、LDL的影响更加显著,差异有统计学意义（P＜0.05）。结论:结直肠癌患者在术后辅助化疗期间存在血脂代谢紊乱,以血清TG、HDL、LDL升高为特点;不同化疗方案对血脂变化的影响存在差异。     

血脂与激素受体阴性乳腺癌远处转移及疗效的关系

目的 测定激素受体阴性乳腺癌患者的血脂水平,探讨血脂异常与远处转移的关系,及化疗后血脂水平变化与近期疗效的关系。方法 收集154例激素受体阴性乳腺癌患者的临床病理资料和空腹血脂水平,远处转移组患者化疗2周期后第14天再次测定血脂水平。χ²检验分析临床病理特征及基线血脂水平与远处转移的关系,Logistic回归分析远处转移的独立危险因素,配对t检验分析远处转移组患者化疗后血脂各指标变化与疗效关系。结果 乳腺癌远处转移与肿块大小、区域淋巴结转移、组织学分级、高TC、高TG及高LDL-C血症有关(P＜0.05)。Logistic回归分析显示,肿块大小(OR=1.563)、区域淋巴结转移(OR=1.983)、高TC血症(OR=1.502)、高TG血症(OR=1.877)是远处转移的独立危险因素。远处转移组中化疗有效组(PR+SD),TC、TG及LDL-C水平有降低趋势,HDL-C水平有升高趋势,疗效PR组TG水平降低有统计学意义。结论 高脂血症与激素受体阴性乳腺癌远处转移相关,有效的抗肿瘤治疗可降低血脂水平。动态监测血脂水平可作为激素受体阴性乳腺癌远处转移及疗效评价的辅助参考指标。     

2型糖尿病患者血清糖化血红蛋白水平与甲状腺癌发病风险的关系

目的:检测2型糖尿病（T2DM）患者血清糖化血红蛋白（HbA1c）水平，探讨血清HbA1c水平与甲状腺癌发病风险的关系。方法:选取2017年1月至2019年6月在本院收治的T2DM患者（观察组）328例作为研究对象，其中未并发甲状腺癌T2DM患者（未并甲状腺癌组）297例，并发甲状腺癌T2DM患者（并甲状腺癌组）31例，选取同期健康体检者（对照组）330例作为对照。采集受试者清晨空腹外周血并提取血清，全自动生化分析仪检测血清HbA1c、总胆固醇（TC）、三酰甘油（TG）、高密度脂蛋白胆固醇（HDL-C）以及低密度脂蛋白胆固醇（LDL-C）水平；Pearson法分析T2DM患者血清HbA1c水平与TC、TG、HDL-C、LDL-C水平的相关性；采用多因素Logistic回归分析影响T2DM患者并发甲状腺癌的因素。结果:与对照组相比，观察组T2DM患者血清HbA1c、TC、TG、LDL-C水平、甲状腺癌发病率均明显升高（P<0.05），HDL-C水平明显降低（P<0.05）；T2DM患者血清HbA1c水平与TC、TG水平明显正相关（P<0.05），与HDL-C水平明显负相关（P<0.05）；与未并甲状腺癌组相比，并甲状腺癌组T2DM患者血清HbA1c、TC、TG水平明显升高（P<0.05），HDL-C水平明显降低（P<0.05），LDL-C水平无明显变化（P>0.05）；血清HbA1c、TC、TG水平均为影响T2DM患者并发甲状腺癌的危险因素（P<0.05），血清HDL-C水平为影响T2DM患者并发甲状腺癌的保护因素（P<0.05）。结论:T2DM患者并发甲状腺癌可能与血清HbA1c水平升高有关，HbA1c可能通过调控血脂水平，增加T2DM患者并发甲状腺癌的风险，可作为临床上判断T2DM患者并发甲状腺癌风险的依据。     

血清血脂水平与Ⅳ期非小细胞肺癌患者生存预后的相关性

摘 要：［目的］ 评估Ⅳ期NSCLC患者血清血脂水平与预后的关系,寻找Ⅳ期NSCLC预后的潜在因子。［方法］ 回顾性分析239例Ⅳ期NSCLC患者的临床资料,收集治疗前血清总胆固醇（total cholesterol,TC）、甘油三酯（triglyceride,TG）、高密度脂蛋白胆固醇（high density lipoprotein cholesterol,HDL-C）和低密度脂蛋白胆固醇（low density lipoprotein cholesterol,LDL-C）水平。无进展生存期（progression free survival,PFS）和总生存期（overall survival,OS）是主要结局指标。用X-tile软件确定各个指标的最佳截断值,生存分析采用Kaplan-Meier法和Cox风险比例模型分析。［结果］ 与血脂低水平组相比,TC高值组（TC≥5.02 mmol/L）具有更好的PFS（P=0.021）和OS（P=0.001）。TG高值组（TG≥0.97 mmol/L）具有更好的OS（P=0.024）。HDL-C高值组（HDL-C≥1.19 mmol/L）具有更好的PFS（P＜0.001）和OS（P=0.024）。LDL-C高值组（LDL-C≥3.27 mmol/L）具有更好的OS（P=0.006）。Cox多因素回归分析表明,HDL-C是影响Ⅳ期NSCLC患者PFS（P=0.012）和OS（P=0.030）的独立预后因素。［结论］ 治疗前血清TC、TG、HDL-C和LDL-C水平可能是Ⅳ期NSCLC患者的重要预后因素。     

老年甲状腺癌患者术前血脂、尿酸水平与术后淋巴结转移的相关性

目的:探讨老年甲状腺癌患者术前血脂、尿酸水平与患者术后颈淋巴结转移的关系。方法:回顾性分析,收集2017年4月至2019年10月期间我院完成手术治疗与随访的141例老年甲状腺癌患者作为甲状腺癌组,并收集同期我院体检证实为健康的138例老年人群作为对照组,检测并比较两组血脂及尿酸水平,根据老年甲状腺癌患者术后有无发生颈淋巴结转移将其分为转移组与未转移组,对比两组血脂及尿酸水平,分析血脂水平与尿酸水平之间的相关性及其各自与老年甲状腺癌患者术后颈淋巴结转移的关系。结果:甲状腺癌组与对照组HDL-C水平对比,差异无统计学意义（P＞0.05）;甲状腺癌组TG、TC、LDL-C水平均高于对照组,尿酸水平低于对照组,差异有统计学意义（P＜0.05）;141例老年甲状腺癌患者转移80例;转移组与未转移组HDL-C水平对比,差异无统计学意义（P＞0.05）;转移组TG、TC、LDL-C水平均高于未转移组,尿酸水平低于未转移组,差异有统计学意义（P＜0.05）;相关性分析结果显示,老年甲状腺癌血脂各主要指标与尿酸两两间均呈正相关（r＞0,P＜0.05）;经回归分析结果显示,术前TG、TC、LDL-C高表达、尿酸低表达是术后颈淋巴结转移的影响因素（OR＞1,P＜0.05）;经ROC曲线分析结果显示,术前TG、TC、LDL-C及尿酸水平预测老年甲状腺癌术后颈淋巴结转移的曲线下面积（AUC）均＞0.80,预测价值较理想。结论:术前TG、TC、LDL-C、尿酸表达异常均可能是老年甲状腺癌患者术后颈淋巴结转移的影响因素,临床可通过检测患者术前TG、TC、LDL-C及尿酸水平预测术后颈淋巴结转移风险,为术后制定合理化康复方案提供指导。     

结直肠癌患者手术前后胸苷酸磷酸化酶（TP）的表达及临床意义

目的：研究结直肠癌组织和血清中胸苷磷酸化酶（thymidine phosphorylase TP）表达与病理及生物特性之间的关系。方法：对50例结直肠癌标本、20例正常结直肠黏膜标本及18例结直肠良性病变组织进行免疫组化S—P法检测,测定TP表达情况;ELISA法测定结直肠癌患者术前、术后血清TP水平及20例健康志愿者血清TP水平。结果：结直肠癌组织中胸苷磷酸化酶表达的阳性率显著高于正常结直肠黏膜、结直肠良性病变（P〈0．05）;有淋巴结转移的结直肠癌组TP表达阳性率高于无淋巴结转移组（P〈0．05）;结直肠癌组血清TP水平较健康组为高,差别具有统计学意义（P〈0．05）;DukesA—B期和DukesC—D期患者之间血清TP水平比较差别具有统计学意义（P〈0．05）。术前和术后结直肠癌患者血清,TP水平差别具有统计学意义（P〈0．05）。结论：结直肠癌Dukes分期较晚及有淋巴结转移者,其瘤组织中TP表达的阳性率高;血清胸苷磷酸化酶的水平与患者的肿瘤病理分期有关,分期越晚表达水平越高;胸苷磷酸化酶在组织中的表达与其血清的水平呈正相关性,血清胸苷磷酸化酶的水平可以反应其组织中的表达水平。     

乳腺癌患者化疗前后血脂和体质量指数的变化及其意义

目的 研究乳腺癌患者辅助及新辅助化疗前后血脂水平和体质量指数的变化及其意义.方法 选取106例接受化疗(新辅助化疗和辅助化疗)的乳腺癌患者,在化疗前和化疗疗程结束后1月查体时分别检验每位患者的血脂水平及计算其体质量指数,将所得数据进行统计分析.结果 (1)化疗后与化疗前比较,血清总胆固醇(total cholesterol,TC)、总甘油三酯(triglyceride,TG)、低密度脂蛋白胆固醇(low density lipoprotein cholesterol,LDL-C)水平及体质量指数均有升高(P＜0.05),高密度脂蛋白胆固醇(high density lipoprotein cholesterol,HDL-C)水平没有升高(P＞0.05).(2)4组化疗方案(CEF、FE100C、TEC、EC-T)中,EC-T方案组患者化疗后TC、TG、LDL-C水平及体质量指数均高于其余3组化疗方案患者,两两比较差异有统计学意义(P＜0.05),而HDL-C水平比较差异无统计学意义(P＞0.05).(3)以患者恶心、呕吐反应为依据分组分析,Ⅲ～Ⅳ度恶心、呕吐组与Ⅰ～Ⅱ度恶心、呕吐组比较,TC、TG、LDL-C水平及体质量指数均有升高(P＜0.05),HDL-C水平没有升高(P＞0.05).结论 乳腺癌患者在化疗(新辅助及术后辅助化疗)过程中要注意饮食营养均衡,尤其是恶心、呕吐反应症状较轻者,不宜过度饮食,避免化疗后体质量指数及血脂增高明显,预防相关疾病发生.     

多发性骨髓瘤患者血脂的检测及临床意义

目的:探讨分期不同的多发性骨髓瘤患者化疗前后血脂水平变化的临床意义。方法:回顾性分析西南医科大学附属医院2013年05月至2018年08月121例初诊多发性骨髓瘤患者一般资料,并以体检中心健康人群作为正常对照组,比较多发性骨髓瘤不同分期的总胆固醇（TC）、甘油三酯（TG）、高密度脂蛋白胆固醇（HDL-C）、低密度脂蛋白胆固醇（LDL-C）、白蛋白（ALB）水平,比较48例多发性骨髓瘤患者化疗前后血脂及白蛋白、β2微球蛋白水平。结果:多发性骨髓瘤不同分期的血脂水平不同,Ⅲ期TC、HDL水平最低,患者化疗后血脂水平较化疗前有所升高,化疗后β2微球蛋白水平较化疗前降低。结论:血脂的监测对疾病的进展及化疗效果的判断有重要的临床意义。     

Serum lipid profile in colorectal cancer patients with and without synchronous distant metastases

OBJECTIVE: In this study, the serum lipid profile, including total cholesterol (TC), triglycerides (TG), high-density (HDL-C) and low-density lipoprotein cholesterol (LDL-C), has been investigated in colorectal cancer patients (CRC) with and without synchronous distant metastases. The aim of this study was to verify whether the presence of metastases was associated to serum lipid abnormalities, and whether lipoprotein abnormalities were linked to the nutritional status. METHODS: The fasting serum lipid profile was examined in 84 CRC patients using colorimetric methods. To determine the nutritional status, the body mass index (BMI) was calculated and serum albumin was measured. RESULTS: Patients with distant metastases showed significantly higher levels of TC, LDL-C and the LDL-C/HDL-C ratio than patients without metastases (p< 0.05). The presence of metastases was positively associated with TC, LDL-C and the LDL-C/HDL-C ratio, being independent of sex, age and BMI. CONCLUSIONS: Elevated serum lipid levels may facilitate the development of distant metastasis in CRC patients.     

大肠癌患者血脂及脂蛋白变化的临床意义

目的：流行病学研究发现血清胆固醇水平与一些癌症的发生和死亡率呈负相关。本文旨在评价大肠癌（ＣＲＣ）患者血脂及脂蛋白水平与ＣＲＣ分化程度、Ｄｕｋｅ氏分期和预后的关系。方法：应用自动生化分析仪，测定了进展期ＣＲＣ患者（ｎ＝７６），良性大肠疾病患者（ｎ＝４０）和正常对照者（ｎ＝６０）的血脂和脂蛋白水平，分别用ｔ检验、方差分析或Ｋａｐｌａｎ－Ｍｅｉｅｒ曲线Ｌｏｇ－ｒａｎｋ检验等对结果进行统计分析。结果：ＣＲＣ患者血清总胆固醇（ＴＣ）和高密度脂蛋白胆固醇（ＨＤＬ－Ｃ）水平明显低于良性大肠疾病组和正常对照组（Ｐ＜００２或Ｐ＜００１）。分化不良的ＣＲＣ患者的血清ＴＣ和ＨＤＬ－Ｃ水平显著低于分化良好者（Ｐ＜００５）。根据Ｄｕｋｅ氏分期，随着ＣＲＣ的进展，患者的血清ＴＣ和ＨＤＬ－Ｃ水平逐渐下降。血清ＴＣ和ＨＤＬ－Ｃ水平正常的ＣＲＣ患者的６个月生存率明显高于血清ＴＣ和ＨＤＬ－Ｃ水平下降者（Ｐ＜００５）。结论：大肠癌患者血清ＴＣ和ＨＤＬ－Ｃ水平下降，并可能与大肠癌的分化程度、Ｄｕｋｅ氏分期和患者的预后有关。     

Could Anthropometric and Lipid Parameters Reflect Susceptibility to Breast Cancer? Comparison of Newly Diagnosed Breast Cancer and Apparently Healthy Women

Objectives: To determine and compare the serum lipid profiles and anthropometric parameters of newly diagnosedBC patients and healthy women. Methods: Serum total cholesterol (TC), high density lipoprotein cholesterol (HDL-C),low density lipoprotein cholesterol (LDL-C), very low density lipoprotein cholesterol (VLDL-C), triglyceride (TG)and TC: HDL-C were measured in consent obtained newly diagnosed BC patients (n=155) and age matched apparentlyhealthy females (n=75). Weight (W), height (H), waist circumference (WC), hip circumference (HC) and mid upper armcircumference (MUC) of each women were recorded. Cut off values for each parameter was found by receiver operativecharacteristic (ROC) curves and risk associated with was calculated using SPSS version 16. Results: Majority (67%)of BC women were postmenopausal. The mean TC, HDL-C, LDL-C, VLDL-C, TC: HDL-C, TG concentrations ofBC patients who were not on cholesterol lowering drugs (n= 126) were 234 mg/dL (±51), 43 mg/dL (±10), 164 mg/dL(±44), 27 mg/dL (±14), 5.7(±1.7) and 135 mg/dL (±69) respectively. TC, LDL-C and TC: HDL-C of BC patients weresignificantly elevated when compared with healthy females. Significant difference in serum lipid profile parameters wasnot observed (p> 0.05) according to the menopausal status of BC and healthy women. One third (30.3%) of BC patientswere overweight and 45% were obese. Majority had elevated WC (72%), W: H ratios (89%) and MUC (89%). BMI,W: H and MUC of BC women were significantly higher (p<0.05) when compared with healthy females. Conclusions:The lipid parameters TC, LDL-C and TC: HDL-C above 203 mg/dL, 139 mg/dL and 3.9 respectively were risk factors.Among anthropometric measures, BMI>25 kg/m2 showed the highest risk while elevated W:H and MUC were alsosignificant risk factors among the study group.     

Effects of toremifene (TOR) and tamoxifen (TAM) on serum lipids

This study clarified the difference in the effects on serum lipids between toremifene (TOR) and tamoxifen (TAM). To remove influencing factors, we investigated adjuvant therapy for hormone receptor-positive patients with breast cancer without lymph node metastasis. The subjects were 65 patients who were enrolled in a multicenter randomized comparative study between April 1997 and March 2001. As adjuvant therapy, 20 mg of TAM or 40 mg of TOR was administered for 1 year. The levels of triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein A-1 (Apo A-1), apolipoprotein A(Apo B), and lipoprotein a (Lp(a)) were measured prior to administration and 3, 6, and 12 months after the start of administration. TC, LDL-C, Lp(a) and Apo B significantly decreased from the third month of administration compared with values before the start of administration in both the TOR and TAM groups. HDL-C significantly increased from the third month only in the TOR group. TG significantly increased in the TAM group but significantly decreased in the TOR group in the 12th month of administration. When these two groups were compared, HDL-C was significantly higher ( p < 0.01) and TG was significantly lower ( p < 0.01) in the TOR group in the 12th month. Improvement of abnormal values of TG, HDL-C and LDL-C was better in the TOR group than in the TAM group after administration for 12 months. The effect on lipid metabolism showed different profiles between the two selective estrogen receptor modulators (SERMs), and TOR gave better results than TAM.     

The effect of exemestane,anastrozole, and tamoxifen on lipid profiles in Japanese postmenopausal early breast cancer patients: final results of National Surgical Adjuvant Study BC 04, the TEAM Japan sub-study

BackgroundIn this Tamoxifen Exemestane Adjuvant Multinational Japan sub-study, we evaluated the time course of changes in serum lipids in postmenopausal women with hormone-sensitive early breast cancer treated with exemestane, anastrozole, or tamoxifen for postoperative adjuvant therapy.Patients and methodsA total of 154 breast cancer patients were assigned to receive exemestane, anastrozole, or tamoxifen in this randomized open-label study. Serum lipid parameters including triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) were measured during 1 year of treatment.ResultsTC and LDL-C rapidly decreased in patients treated with tamoxifen at 3 months. Compared with anastrozole and exemestane patients, TC and LDL-C were significantly lower at all assessment time points in tamoxifen patients (P < 0.05). TG increased in tamoxifen patients; it was significantly higher compared with exemestane patients at all assessment time points (P < 0.05). HDL-C slightly decreased in exemestane patients; it was significantly lower compared with anastrozole patients at 3 months and 1 year (P = 0.0179 and 0.0013, respectively).ConclusionChanges of lipid profiles in Japanese postmenopausal women treated with tamoxifen were relatively favorable, while exemestane and anastrozole had no clinically significant effect on the serum lipids.     

2型糖尿病血糖、血脂代谢情况与甲状腺癌发病的相关性

目的 探讨2型糖尿病血糖、血脂代谢情况与甲状腺癌发病的相关性.方法 将467例门诊确诊为2型糖尿病的患者纳入研究组,同时将同期健康体检者200例纳入对照组.检测入选者血清血糖(GLU)、胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白(HDL-C)、低密度脂蛋白(LDL-C)、游离三碘甲状腺原氨酸(FT3)、游离甲状腺素(FT4)和促甲状腺激素(TSH)水平并进行统计分析.结果 观察组甲状腺癌的发病率为9.2%,显著高于对照组的1.5%,差异有统计学意义(P<0.05).观察组血清TC、TG和LDL-C明显高于对照组,HDL-C明显低于对照组,差异有统计学意义,P<0.05.观察组患者血清FT3显著高于对照组,TSH显著低于对照组,差异有统计学意义(P<0.05).结论 2型糖尿病患者血糖和血脂紊乱会增加甲状腺癌的发病率,可能是通过影响甲状腺激素的分泌实现的.     

乳腺癌患者血清PCSK9及血脂水平的检测及临床意义

目的:探讨PCSK9在乳腺癌患者血清中的水平及其与血脂水平的相关性。方法:选取从2018年01月至2019年12月在我院就诊的139例乳腺癌术后患者和125名健康体检者为对照组。测定PCSK9、总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)水平,分析在乳腺癌患者血清中的相关性。结果:PCSK9水平在乳腺癌患者中明显高于对照组(P＜0.05)。在乳腺癌患者中TC和LDL水平明显高于对照组,而HDL水平明显低于对照组(P＜0.05)。结论:PCSK9和血脂水平与乳腺癌相关,检测PCSK9和血脂水平可为乳腺癌的早期诊断、筛查及精准治疗提供依据。     

Comparative effects of anastrozole, tamoxifen alone and in combination on plasma lipids and bone-derived resorption during neoadjuvant therapy in the impact trial.

BACKGROUND: Estrogen has beneficial effects on lipid metabolism and bone preservation. The IMPACT trial evaluated neoadjuvant therapy with anastrozole or tamoxifen alone, or a combination. The comparative effects of these treatments on serum lipids and bone resorption were assessed. PATIENTS AND METHODS: Non-fasting clotted blood samples were taken from 176 postmenopausal patients at baseline, 2 and 12 weeks for assessment of serum levels of estradiol, the bone resorption marker CTx and lipid profiles [total cholesterol (TC), high density lipoprotein cholesterol (HDL-C) and non-HDL cholesterol (N-HDL-C)]. RESULTS: After 12 weeks, tamoxifen was associated with a significant increase in HDL-C (26.5%), and a decrease in TC (6.5%) and N-HDL-C (12.3%). Anastrozole was associated with a significant increase in HDL-C (11.2%), and a non-significant increase in TC (2.9%) and N-HDL-C (3.4%), both of which were significantly different from tamoxifen. The combination was associated with a significant increase in HDL-C (9.4%), and a decrease in TC (10.9%) and N-HDL-C (13.9%). For tamoxifen and the combination, there were non-significant decreases in CTx compared with a significant increase (45.6%) with anastrozole. No correlation between serum estradiol and CTx was seen in any of the treatment groups. CONCLUSION: Anastrozole did not have a detrimental effect on lipid profiles following 3 months of therapy. There was a significant increase in CTx with anastrozole in contrast to tamoxifen.     

放疗对头颈部恶性肿瘤患者的心血管疾病危险因素水平的影响

目的 探讨放疗对头颈部恶性肿瘤患者的心血管疾病危险因素水平的影响.方法 以经病理确诊为头颈部恶性肿瘤并接受放疗的40例患者作为观察组;以病理确诊为头颈部恶性肿瘤但还未接受放疗的40例患者作为对照组.比较两组的收缩压(SBP)与舒张压(DBP)、总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白-胆固醇(LDL-C)、高密度脂蛋白-胆固醇(HDL-C)、空腹血糖(FPG)和体重指数(BMI)水平.结果 观察组的SBP、DBP、TC、TG、LDL-C和FPG水平均明显高于对照组(P<0.05),观察组的HDL-C水平明显低于对照组(P<0.05),两组的BMI差异不明显(P>0.05);放疗前后观察组高血压、血脂异常、超重或肥胖以及糖尿病的患病例数差异不具有统计学意义(P>0.05),但放疗后例数均略多于放疗前.结论 放疗会影响头颈部恶性肿瘤患者CVD危险因素水平,CVD危险因素水平的监测可为对头颈部恶性肿瘤患者的CVD防治提供一定参考.